Navigation Links
FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
Date:2/3/2009

label clinical studies of Cinryze for both acute treatment and routine prophylaxis against angioedema attacks.

The Phase 3 acute treatment study was a randomized, double blind, placebo controlled multi-center trial in 71 patients evaluating the safety and efficacy profile of Cinryze for treatment of HAE attacks. The primary efficacy measure in the pivotal Phase 3 acute treatment study was the time from initial treatment to the start of unequivocal relief of the defining symptom. Based on the primary efficacy variable, in the All Randomized (ITT) Dataset, the likelihood of a patient having the start of unequivocal relief of the defining symptom was 2.048 times greater in the Cinryze treatment group than in the placebo treatment group (p=0.048). The median time to the start of unequivocal relief of the defining symptom was shorter in subjects in the Cinryze treatment group (two hours) than in subjects in the placebo treatment group (greater than four hours).

In the open label study of Cinryze as treatment for acute attacks of HAE, no patients who had acute laryngeal edema attacks required hospitalization or intubation. Cinryze was generally well tolerated. There were no deaths or serious adverse reactions related to Cinryze administration, or discontinuations due to treatment-emergent adverse events. In the analysis of 447 acute attacks in 82 patients, open label Cinryze administration provided substantial relief of the defining symptom in 93.4 percent of the attacks within four hours of injection, with a median time to onset of relief of 30 minutes. There was no observed loss of effectiveness over multiple administrations of Cinryze for subsequent HAE attacks.

About Cinryze C1 Inhibitor (human)

Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 inhibitor product that has been approved by FDA for routine prophylaxis against angioedema attacks in adolescent and adult patie
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
2. Chinese SFDA Grants Immtech Fast Track Status
3. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
4. NTMir Announces Research Grants for Epidemiology and Household Water as Source of Infection
5. FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents
8. FDA Grants Priority Review for PROMACTA(R) (eltrombopag)
9. FDA Grants NeoVistas Request to Expand CABERNET Trial to 30 Sites in the U.S.
10. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
11. FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 PuraMed BioScience®, Inc., (OTC Pink: ... medicinal and healthcare products, announced it received the initial ... hemp-based, advanced headache relief product, for planned distribution to ... Colorado , Washington State , ... the MigraPure H Advanced headache relief gel formulation completed, ...
(Date:12/24/2014)... Dec. 23, 2014   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... of the Marketing Authorization Application (MAA) for sebelipase ... the company,s request for accelerated assessment, which has ... time.   The MAA, and the ...
(Date:12/24/2014)... Calif. , Dec. 23, 2014 In response ... Doctors, Association of Sierra Leone , Direct ... Leone for the treatment of local health workers ... While a new dedicated Ebola care center was constructed for ... the facility is not available for local Sierra Leonean health ...
Breaking Medicine Technology:PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2
... RAD001 reduces risk of disease progression by 70%, - RAD001 is first and ... Nexavar(R),** with potential to address ... unmet medical need,- Once-daily oral RAD001 directly targets ... and blood vessel growth, - RAD001 is currently being studied in multiple types ...
... Adding Singulair to Advair Offers no Additional ... Improvement in Overall Asthma ... 18 /PRNewswire-FirstCall/,-- Patients with both asthma and allergic rhinitis, ... with Advair,Diskus(R) (fluticasone propionate and salmeterol inhalation powder) as,compared ...
Cached Medicine Technology:RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 2RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 3RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 4RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 5RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 6Patients With Asthma and Seasonal Allergies Respond Better to Advair(R) for Their Asthma Than Singulair(TM) 2Patients With Asthma and Seasonal Allergies Respond Better to Advair(R) for Their Asthma Than Singulair(TM) 3
(Date:12/25/2014)... California (PRWEB) December 25, 2014 Plugin ... of ProFire 5k. A fully customizable business presentation tool ... , “Adding the ProFire 5k business tool, users can ... Christina Austin, CEO of Pixel Film Studios. “ProFire 5k ... and style to add professionalism to a presentation” , ...
(Date:12/25/2014)... AZ (PRWEB) December 25, 2014 Parker ... to outstanding customer service and affordable quality regarding heating, ... area announces recognition in 2014 by the “Queen of ... Sons has earned an impressive reputation over the years ... on a wide range of contractor services for both ...
(Date:12/24/2014)... Epigenetics finds applications in a large ... drug discovery, developmental biology, and research for metabolic and ... the most widely used techniques for the discovery and ... of cancer is rapidly growing worldwide. In 2012, there ... deaths, and 32.6 million people living with cancer (within ...
(Date:12/24/2014)... 2014 Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) ... litigation currently underway in Pennsylvania’s Philadelphia Court of Common ... 24, 2014, court documents indicate that 1,183 claims had ... who developed gynecomastia (male breast growth) and other complications ... indicates that this represents an increase of more than ...
(Date:12/24/2014)... 2014 The federal court overseeing ... blood thinner caused life-threatening episodes of internal bleeding ... for the proceeding, Bernstein Liebhard LLP reports. According ... plans to select lawyers to serve as Liaison ... appointing a Plaintiffs’ Steering Committee, which will coordinate ...
Breaking Medicine News(10 mins):Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3
... Uroplasty, Inc. (Amex:,UPI) announced today that it ... Fourth Annual Equity Conference which will be held ... the Loews Lake Las Vegas Resort, NV.,Dave Kaysen, ... Vice,President and Chief Financial Officer will discuss the ...
... Aug. 11 ,BlueCross BlueShield of Tennessee (BCBS-T) has ... settle allegations of violating the False Claims,Act, the ... Chattanooga, Tenn., operates as Riverbend Government Benefit,Administrators., ... primary,Medicare Part A Fiscal Intermediary for the state ...
... access and practical ... ... for medical professionals, today announced the availability,of PubMed,s MEDLINE abstracts at ... U.S. National Library,of Medicine,s MEDLINE index. SearchMedica,s MEDLINE abstracts link back ...
... Nation Using Caregiverlist.com to Find Quality ... ... nation,s online,destination dedicated to connecting seniors with quality senior care,choices, is ... care services as the caregiving recruitment source for the,industry. Nearly 1,000 ...
... Cardiovascular Disease (GICD) and UCSF have identified a key ... system, the extensive network of arteries, veins, and ... organs. The research, published in the latest issue of ... therapeutic targets for a wide variety of diseases, such ...
... Cincinnati Sub-Zero Medical receives Governor,s 2008 Excellence in Exporting Award (,E-Award,), ... Strickland and Lieutenant Governor Lee Fisher present award to CSZ Chairman ... ... August 11, 2008 -- Cincinnati Sub-Zero (CSZ) Medical, a division of ...
Cached Medicine News:Health News:Uroplasty to Present at the Noble Financial Fourth Annual Equity Conference 2Health News:BlueCross BlueShield of Tennessee to Pay U.S. $2.1 Million to Resolve False Claims Act Allegations 2Health News:SearchMedica.com Connects Medical Professionals With MEDLINE Abstracts 2Health News:Home Care Agencies Staffing Challenge Solved With Caregiverlist.com 2Health News:Gladstone scientists identify single microRNA that controls blood vessel development 2Health News:Gladstone scientists identify single microRNA that controls blood vessel development 3Health News:State of Ohio Recognizes Cincinnati Sub-Zero for Excellence in International Sales 2Health News:State of Ohio Recognizes Cincinnati Sub-Zero for Excellence in International Sales 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: